PatternsRadar
Sign in

BAJAJHCAREBajaj Healthcare Limited

NSE
Full chart
323.10INR+4.00 (+1.25%)Close · 6 Oct 2026
20 Jul 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹1,088 CrMarket cap
61.7P/E (TTM)
56.1%Delivery

Filings & corporate actions

18 results filed
CSV
Next results · Q2 FY27
Expected 17 Oct 2026 – 15 Nov 2026
Estimate: filed 17–46 days after quarter end, last 4 times
Dividend
₹1.50 per share · last 11 Sept 2026
2026
  • 11 SeptdividendDividend · ₹1.50 per share+0.2%
  • 20 JulresultsResults · Q1 FY27 · standalone-4.4%NSE
  • 15 JulshareholdingShareholding · 30 Jun 2026+4.6%NSE
  • 8 MayresultsResults · Q4 FY26 · standalone-9.5%NSE
  • 17 AprshareholdingShareholding · 31 Mar 2026-0.6%NSE
  • 25 MarshareholdingShareholding · 18 Mar 2026+2.2%NSE
  • 19 JanshareholdingShareholding · 31 Dec 2025+0.2%NSE
  • 16 JanresultsResults · Q3 FY26 · standalone+0.2%NSE

Reaction to results · all yearsrose on day 0 in 5 of 18 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2720 Jul 2026-4.4%-16.8%-16.6%0.8×
Q4 FY268 May 2026-9.5%-18.3%-13.2%4.9×
Q3 FY2616 Jan 2026+0.2%-15.0%-8.5%4.8×
Q2 FY2617 Oct 2025-2.1%-3.8%-7.2%0.2×
Q1 FY2628 Jul 2025-2.6%-11.7%-18.3%3.2×
Q4 FY2527 May 2025-0.7%-5.8%-5.4%0.7×
Q3 FY2512 Feb 2025+9.9%+16.6%+7.0%1.0×
Q2 FY2515 Nov 2024-2.6%+2.0%+20.0%1.4×
Q1 FY2514 Aug 2024-3.6%-2.0%-7.6%1.4×
Q4 FY2425 May 2024-2.2%-5.8%+10.7%2.9×
Q3 FY2410 Feb 2024-7.6%-1.1%-2.3%2.4×
Q2 FY2410 Nov 2023-4.8%-0.3%-7.7%1.4×
Q1 FY2414 Aug 2023-1.4%-6.2%+25.1%2.3×
Q4 FY2331 May 2023-0.9%-2.4%+7.4%1.7×
Q2 FY2311 Nov 2022+0.7%+6.8%+16.9%0.7×
Q1 FY2313 Aug 2022+1.4%-4.2%+0.7%1.0×
Q4 FY2218 May 2022+9.2%+2.9%-5.0%8.4×
Q3 FY2228 Jan 2022-1.9%+3.4%-5.4%1.4×
Average-1.3%-3.4%-0.5%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+11.3%
Profit YoY+15.8%
Interest cost YoY-6.4%
Revenue QoQ+8.2%
Profit QoQ—
CAGR2Y3Y4Y5Y6Y7Y
Revenue+14.9%—————
Profit——————

Key data

CSV
Open323.00
Day range317.50 – 324.00
52-week range272.35 – 509.90
From 52w high-36.6%
RSI (14)44.0
ATR (14)11.16
Volume79.5K
Avg volume (20D)1.35L
Rel volume0.59×
Volatility (1Y)42.3%
Turnover₹2.6Cr
SMA 50 / 200329.16 / 337.16

Delivery percentage

Latest · 6 Oct 202656.1%
20-day avg49.1%
1-year avg42.2%
Percentile (own history)80th
Range4.8–85.6%
Sessions1,203

Over the last 20 sessions BAJAJHCARE settled 49.1% of its traded quantity, which is above average for an NSE equity. Its one-year average is 42.2%, so recent sessions are running 6.9 points higher than usual. The latest session ranks higher than 80% of the 1,203 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price+1.25%-4.01%-0.65%-2.55%+3.84%-31.59%

Valuation

CSV
Market cap₹1,088 Cr
P/E (TTM)61.7
EPS (TTM)5.24
Shares outstanding3.37Cr
Listed25 Nov 2021

Ownership

CSV
Promoter58.59%
Promoter Δ QoQ+0.30 pp
Public41.41%
FII2.19%
DII1.92%
Pledged0.00%

Quarterly results · standalone

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)147.9161.2153.1165.6
YoY chg+11.1%+31.3%-0.9%+11.3%
Net profit (₹ Cr)11.115.7(22.9)13.7
YoY chg+17.4%+33.7%-304.4%+15.8%
Net margin7.5%9.7%-14.9%8.3%
EPS3.474.87-7.154.06

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 58.59% · public 41.41%
19 Nov 2021: promoter 67.26%31 Dec 2021: promoter 67.26%31 Mar 2022: promoter 67.26%30 Jun 2022: promoter 67.30%30 Sept 2022: promoter 67.30%31 Dec 2022: promoter 67.42%31 Mar 2023: promoter 67.49%30 Jun 2023: promoter 67.49%30 Sept 2023: promoter 67.69%31 Dec 2023: promoter 67.73%31 Mar 2024: promoter 67.73%30 Jun 2024: promoter 67.73%19 Sept 2024: promoter 59.19%30 Sept 2024: promoter 59.19%31 Dec 2024: promoter 59.19%31 Mar 2025: promoter 59.19%30 Jun 2025: promoter 59.19%30 Sept 2025: promoter 59.19%31 Dec 2025: promoter 59.19%18 Mar 2026: promoter 58.29%31 Mar 2026: promoter 58.29%30 Jun 2026: promoter 58.59%
2021-112026-06
  • Promoter
  • Public and others
Promoter
58.59%
Public
41.41%
Promoter change
+0.30 pp
Filed
15 Jul 2026
FII
2.19%
DII
1.92%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
Standalone
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26AQ1 FY27
Revenue from operations101.2108.6133.9132.2133.1122.8154.5148.8147.9161.2153.1165.6
Other income1.20.86.50.92.62.413.60.91.71.63.00.8
Total income102.4109.4140.4133.1135.7125.2168.0149.7149.6162.9156.0166.4
Total expenses97.2103.0131.2122.9123.2113.5156.3135.2133.6143.6143.6150.0
└ Finance costs8.36.76.08.47.95.56.15.25.65.95.66.1
└ Depreciation6.77.47.36.76.86.97.55.67.17.27.67.0
Profit before tax5.26.3(35.1)10.212.411.711.714.516.019.2(20.8)16.5
Tax expense0.10.8(3.1)2.24.1(3.3)0.12.43.53.1(1.4)2.6
Net profit(3.5)(2.2)(29.9)7.19.511.711.211.811.115.7(22.9)13.7
EPS-1.25-0.80-10.842.593.363.653.543.743.534.96-7.164.07
Net margin-3.42%-2.02%-22.35%5.39%7.11%9.55%7.24%7.95%7.51%9.72%-14.93%8.27%
PBT margin5.18%5.83%-26.25%7.70%9.35%9.49%7.59%9.76%10.79%11.94%-13.60%9.94%
Tax rate2.30%12.67%—21.19%32.97%-28.43%1.10%16.19%22.01%16.34%—15.59%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 20 Jul 2026.

BAJAJHCARE at a glance

  • BAJAJHCARE closed at ₹323.1 on 6 Oct 2026, +1.25% on the day, -31.6% over one year, 36.6% below its 52-week high of ₹509.9.
  • Delivery was 56.1% of traded quantity on 6 Oct 2026, the 80th percentile of its own 1,203 sessions with a reading (20-session average 49.1%, 1-year average 42.2%).
  • Market capitalisation is ₹1,088 crore at a trailing P/E of 61.7 (trailing EPS ₹5.24).
  • Q1 FY27 results (standalone, filed 20 Jul 2026): revenue ₹166 crore (+11.3% year on year), net profit ₹14 crore (+15.8%); the price moved -4.4% on the first session after.
  • Promoters held 58.59% at 30 Jun 2026, up 0.30 percentage points on the previous filing.
  • Q2 FY27 results are expected between 17 Oct 2026 and 15 Nov 2026, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE411U01027
SeriesEQ
Listed25 Nov 2021
History from25 Nov 2021
Sessions1,206

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE